Early-access Avacopan in Real-world ANCA-associated Vasculitis

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age16+
SponsorLeiden University Medical Center

About this trial

The current study proposal aims to investigate the clinical practice variation of the initial use of avacopan for AAV patients in Europe. The study will describe patient characteristics and organ-specific clinical benefit of avacopan treatment in a unique, first-experience cohort of AAV patients. By studying the clinical practice variation of first-experience avacopan treatment, this study will be uniquely positioned to identify pivotal issues on the real-life implementation of avacopan treatment. These observational data can ultimately serve to address current knowledge gaps on avacopan treatment in AAV patients, improve the care and drug-access for AAV patients with avacopan treatment and generate new areas of research.

Eligibility criteria

Qualifiers

Established diagnosis of GPA or MPA

Treatment (initiation) with avacopan

Informed consent for use of medical data

Disqualifiers

If there is no AAV disease activity present that can be supported by an objectifiable clinical measure or assessment

If a subject is below 16 years old

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

No trial groups listed

Sponsors and collaborators

Leiden University Medical Center

Lead sponsor

University of Udine

Collaborator

University of Modena and Reggio Emilia

Collaborator

Hospital Universitari de Bellvitge

Collaborator

ZOL Hospital Genk Belgium

Collaborator